Breast Implants Presentations

Aortech International PLC
29 April 2005


For immediate release                                            29 April 2005



                           AorTech International plc

                        Next Generation Breast Implants



'AorTech's Elast-Eon breast implant technology introduced at the annual meeting
             of the American Society of Aesthetic Plastic Surgeons'



AorTech International plc is pleased to announce that Dr. Mark Jewell, the
incoming President of the American Society of Aesthetic Plastic Surgeons 
('ASAPS'), and Dr. Leroy Young, the Chairman of the Society's New Technology 
Committee, will today be making presentations regarding AorTech's breast implant 
technology at the Society's Annual Meeting in New Orleans, Louisiana (USA).



These presentations will discuss the advantages of Elast-Eon saline and gel
filled breast implants over current generation technology and will be made as
part of the 'Hot Topics' segment of the Society Meeting.



In the opinion of the Directors of AorTech, based on laboratory tests to date,
the advantages of adopting Elast-Eon in breast implant devices include:



  • Significant reductions in 'bleed' or extractable components
  • No use of metals or other catalysts
  • 50x improvement in shell barrier properties
  • Twice the tear resistance of silicone shells
  • Superior mechanical properties, including abrasion resistance
  • Fatigue resistance testing in excess of 2 billion cycles
  • A wide range of gel elasticity and softness with excellent cohesion  and
    form-stable properties
  • Improved radio transparency
  • Smooth or textured surfaces
  • High consistency manufacturing
  • Biostability comparable to silicone
  • Revolutionary new device manufacturing process



All of which contribute to improved product safety, long term durability, and
patient acceptance of these devices.



Elast-Eon is a biostable copolymer which adopts both the mechanical and
biocompatible advantages of polyurethane and silicone. In laboratory tests, the
material shows significantly enhanced mechanical, wear and tear performance
which makes the application to breast implant devices highly compelling.
Elast-Eon is the result of over 10 years of basic research in high-performance,
biostable polymer technology. Other active applications programs for this
material include heart valves, spinal disc implants, pacing leads and coronary
stents.



The Elast-Eon breast implant development program was commenced in January of
2004 and is in the pre-clinical phase.



AorTech's is actively seeking a substantial industry partner with the resources
and expertise to support the clinical trials and subsequently undertake the
global marketing of these products.



The presentations will be available on the AorTech International plc website,
www.aortech.com.



Commenting on the presentations Frank Maguire, AorTech's Chief Executive, said:



'The support of Drs. Jewell and Young for our Elast-Eon breast implant
technology demonstrates the potential for these devices.



'Having attended the recent FDA Advisory Panel meeting which discussed the
current issues surrounding breast implant technology, I am confident that
AorTech's breast implants can make specific and major improvements to product
safety and patient acceptance.'



In addition, Dr. Mark Jewell commented,



'The Elast-Eon polymer appears quite promising in the development of 5th
generation breast implants that will benefit patients by providing devices made
with advanced biomaterials.'





For further information please contacts:


AorTech International plc                               00 1 801 201 4336
Frank Maguire, Chief Executive

Buchanan Communications                                     020 7466 5000
Ben Willey, Lisa Baderoon, Rebecca Skye Dietrich



Notes to Editors:



AorTech International plc is a public limited company formed under the laws of
Scotland, UK and is traded on the Alternative Investment Market, a market
operated by the London Stock Exchange plc, under the trading symbol AOL.



Additional material concerning AorTech International is available on the
Company's website at www.aortech.com , or may be obtained by contacting the
Company's Investor Relations firm, Buchanan Communications Limited.


                      This information is provided by RNS
            The company news service from the London Stock Exchange